… TERRAIN was a double-blind, randomised phase 2 study, that recruited asymptomatic or
minimally symptomatic men with prostate cancer progression on androgen-deprivation therapy …

… with hormone-naive prostate cancer of varying severity provides a level of disease suppression,
… response and outcomes with enzalutamide in non-castrate men with prostate cancer. …

… Methods In a phase 2, open-label study, patients with … cancer had 50 % CA125 decline and
SD for 10 months with 0.3 mg/kg. We report herein findings from a single-arm, phase 2 trial to …

… We performed a prospective phase 2 study of MRgRT for localized prostate cancer to …
studied using both clinician-scored and patient-reported outcomes. A nonrandomized phase 2 …

… The phase 2 portion of the study evaluates apalutamide activity … We report the phase 2 results
for patients in the nmCRPC … In this phase 2 study of apalutamide, we confirm the safety and …

… -blind Phase 2 study to examine the effect of 30 mg synthetic genistein daily on serum and
tissue biomarkers in patients with localized prostate cancer (CaP). Fifty-four study subjects …

… phase 2 study, the efficacy of olaparib monotherapy in patients with advanced prostate cancer
was … A phase 2 trial of veliparib in combination with abiraterone in patients with metastatic …

… Cancer Society has estimated that, during 2007, about 218,890 new cases of prostate cancer
will be … In this respect, a randomized phase 2 study comparing docetaxel alone versus the …

… We previously reported a phase 2 study of neoadjuvant docetaxel before RP in 19 men with
high-risk localized PCa, demonstrating that treatment was well tolerated and associated with …

… HRPC have demonstrated both a high prostate-specific antigen (PSA) … a single-arm, phase
2 trial of docetaxel plus carboplatin … the neuroendocrine phenotype in prostate cancer and its …